Attached files
| file | filename |
|---|---|
| 8-K - 8-K - AMAG PHARMACEUTICALS, INC. | a17-12172_48k.htm |
Exhibit 12.1
AMAG Pharmaceuticals, Inc.
Statement of Computation of Ratio of Earnings to Fixed Charges
(in thousands, except ratios)
|
|
|
Three Months |
|
Year Ended December 31, |
| ||||||||||||||
|
|
|
2017 |
|
2016 |
|
2015 |
|
2014 |
|
2013 |
|
2012 |
| ||||||
|
Earnings: |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
Income (loss) before income taxes |
|
$ |
(57,266 |
) |
$ |
9,055 |
|
$ |
39,844 |
|
$ |
(17,342 |
) |
$ |
(9,602 |
) |
$ |
(17,604 |
) |
|
Fixed charges |
|
18,642 |
|
74,175 |
|
54,246 |
|
15,247 |
|
657 |
|
954 |
| ||||||
|
Total earnings |
|
$ |
(38,624 |
) |
$ |
83,230 |
|
$ |
94,090 |
|
$ |
(2,095 |
) |
$ |
(8,945 |
) |
$ |
(16,650 |
) |
|
Fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
Interest expense |
|
$ |
18,300 |
|
$ |
73,153 |
|
$ |
53,251 |
|
$ |
14,697 |
|
$ |
— |
|
$ |
— |
|
|
Estimated interest component of rental expense |
|
342 |
|
1,022 |
|
995 |
|
550 |
|
657 |
|
954 |
| ||||||
|
Total fixed charges |
|
$ |
18,642 |
|
$ |
74,175 |
|
$ |
54,246 |
|
$ |
15,247 |
|
$ |
657 |
|
$ |
954 |
|
|
Ratio of earnings to fixed charges(1) |
|
— |
(2) |
1.12 |
x |
1.73 |
x |
— |
(3) |
— |
(4) |
— |
(5) | ||||||
(1) The ratio of earnings to fixed charges is calculated pursuant to the instructions of Item 503 of Regulation S-K and by dividing earnings by fixed charges. For this purpose, “earnings” are determined by adding fixed charges to our income (loss) before income taxes, and “fixed charges” consists of interest expense on our indebtedness as well as the estimated interest component of rental expense (one-third of rent expense, a reasonable approximation of the interest factor) under our operating leases.
(2) Our earnings were insufficient to cover our fixed charges during the three months ended March 31, 2017 by $57.3 million.
(3) Our earnings were insufficient to cover our fixed charges during the year ended December 31, 2014 by $17.3 million.
(4) Our earnings were insufficient to cover our fixed charges during the year ended December 31, 2013 by $9.6 million.
(5) Our earnings were insufficient to cover our fixed charges during the year ended December 31, 2012 by $17.6 million.